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A B S T R A C T
Diuretics have long been cherished as drugs of choice for uncomplicated primary hypertension. Robust
mortality and morbidity data is available for diuretics to back this strategy. Off-late the interest for
diuretics has waned off perhaps due to availability of more effective drugs but more likely due to
perceived lack of tolerance and side-effect proﬁle of high-dose of diuretics required for mortality beneﬁt.
Low-dose diuretics particularly thiazide diuretics are safer but lack the mortality beneﬁt shown by high-
dose. However, indapamide and low dose chlorthalidone have fewer side-effects but continue to provide
mortality beneﬁt.
 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Diuretics, particularly thiazide and thiazide-like diuretics have
been the gold standard of antihypertensive therapy for uncompli-
cated primary hypertension (formerly known as essential hyper-
tension) till recent past. Several trials, even some relatively recent
ones have demonstrated mortality beneﬁt with diuretic therapy in
uncomplicated hypertension.1–3 Several JNC Guidelines have kept
diuretics as ﬁrst-line agent (even drug of choice) in management of
uncomplicated hypertension.4,5 No individual can be labeled as
resistant hypertension unless a concurrent use of 3 antihypertensive
agents of different classes, one of the 3 agents a diuretic, prescribed
at optimal dose has been instituted.6 However, despite robust
clinical data, their use in real-world practice has continued to
decline.7 This is rather intriguing and may be related to several
misconceptions prevailing about use of diuretics in primary
hypertension: (1) the use of diuretics does not result in decrease
in morbidity or mortality; (2) diuretics are poorly tolerated; and (3)
use of diuretics is associated with signiﬁcant adverse metabolic
effects (increased lipid levels, adverse effects on glucose metabo-
lism, effects on arrhythmias, etc.).8–10 The efforts to promote newer
medications may feed on these misconceptions.11–14 However, the
incidence and magnitude of these side effects are much lower with
low-dose therapy (12.5–25 mg of hydrochlorothiazide or chlortha-
lidone) but one cannot assume that the beneﬁts of high dose
thiazides would have replicated with lower doses of hydrochloro-
thiazide as commonly used in the treatment of primary hyperten-
sion. Herein rests the role of indapamide or low dose chlorthalidone.
2. Mortality reduction
The early landmark trials for treatment of hypertension
demonstrated signiﬁcant reduction of stroke, cardiovascular mor-http://dx.doi.org/10.1016/j.ihj.2016.08.013
0019-4832/ 2016 Published by Elsevier B.V. on behalf of Cardiological Society of
creativecommons.org/licenses/by-nc-nd/4.0/).bidity and mortality associated with BP lowering, primarily with
thiazide diuretics (Figs. 1–3).15–18 Relatively recently, head-to-head
comparison between various anti-hypertensive agents, in the
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart
Attack Trial (ALLHAT), chlorthalidone was found superior in
preventing one or more major forms of CV disease.3 A subsequent
meta-analysis also revealed a superiority of thiazide type diuretics
over other anti-hypertensive agents in terms of various adverse CV
outcome reductions.19 A recent meta-analysis involving 12 RCTs
(48 898 patients) revealed a reduction in relative risk for stroke
(37%), heart failure (49%), CAD (18%), cardiovascular death (18%) and
all-cause death (1%), all statistically signiﬁcant. Nine other studies
including secondary analysis (66 788 patients) in which diuretics
were used in association with other drugs, risk reduction with
diuretics was similar.20 In this study, use of diuretics prevented
15 strokes, 24 major cardiovascular events and eight deaths every
1000 patients treated for 5 years (with NNT of 67, 41 and 118,
respectively). Not only uncomplicated primary hypertension, there
is numerous evidence to support the use of diuretics (over other
anti-hypertensives) in several patient populations, so much so that
the use of diuretics features in many treatment guidelines.21–23
3. Concerns with diuretic therapy
Lack of tolerability of diuretics has been a major concern
limiting their use. Available studies reveal that diuretics either do
not interfere with, or may actually improve, quality of life in
hypertensive patients. Particularly, low-dose diuretic treatment is
a well-tolerated and may be an excellent initial choice for
hypertensive patients, even elderly. However, high-dose diuretics
should be avoided, in patients with co-morbidities like diabetes,
gout, or erectile dysfunction in men.24 The potential adverse
metabolic effects of thiazide and thiazide-like diuretics include India. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. Stroke rate reduction with diuretics.
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Fig. 2. Cardiovascular risk reduction with diuretics.
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Fig. 3. Mortality reduction with diuretics.
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metabolism.25,26 Again these side-effects are more common with
high dose therapy. Use of high dose diuretic without a potassium-
sparing agent has been even associated with sudden cardiac
death.27
4. Low dose diuretic therapy
To reduce the side-effects of high-dose thiazide and thiazide-
like diuretics, they are typically used at low doses (12.5–25 mg/day
of chlorthalidone or hydrochlorothiazide, or 1.5 mg of indapamide
SR) which minimizes the metabolic complications, while main-
taining the antihypertensive response.26,28,29 Among the three
anti-hypertensive agents, low doses of chlorthalidone andindapamide were more effective in lowering blood pressure than
hydrochlorothiazide but metabolic abnormalities (although lower
than high dose) were greater with low doses chlorthalidone than
with hydrochlorothiazide or indapamide.29 Thus on balance of
things it appears that indapamide is both effective and safer at low
doses compared with other diuretics. Even though in ALLHAT Trial
low dose chlorthalidone was associated with a plasma potassium
reduction of only 0.2 meq/L, 8.5% patients required potassium
supplements and a signiﬁcantly higher number of non-diabetic
patients at baseline developing elevation of fasting blood glucose
level to values 126 mg/dL compared with amlodipine and
lisinopril (11.6% vs. 9.8% {p = 0.04} and 8.1% {p < 0.001}, respec-
tively).1 Persistent activation of sympathetic nervous system and
insulin resistance could be the reason for increased new onset of
diabetes with chlorthalidone.30
5. Limitations of low dose diuretic therapy
An interesting point is that although low dose thiazide/thiazide
like diuretic therapy minimizes the metabolic complications, it
may not eliminate other side effects; 25% of men treated with
25 mg of chlorthalidone per day develop a decline in sexual
function and sleep disturbances may also occur, particularly if the
patient is also on a low-sodium diet.31 Further, in a meta-analysis
where 8 trials classiﬁed as low dose were compared with 4 trials of
high dose diuretics, stroke rate reduction was much higher with
high-dose and total cardiovascular risk was much lower in high-
dose than in low-dose diuretic trials (cardiovascular death 4.8%,
rather than 17.6% in 10 years).20
6. Are all diuretics equal?
In the International Nifedipine GITS study: Intervention as a
Goal in Hypertension Treatment (INSIGHT) study, while high-dose
hydrochlorothiazide was found to be equal to calcium antagonists
at doses below 25 mg, there was no evidence of reduction in
morbidity and mortality.32 Chlorthalidone is 1.5–2 times as potent
as hydrochlorothiazide and has shown signiﬁcant CV events
reduction vs. both hydrochlorothiazide and placebo.33,18,34 How-
ever, in the largest hypertension trial ALLHAT, low dose
Chlorthalidone (12.5–25 mg daily) was found superior to other
anti-hypertensive agents although metabolic side effects did
occur.3 On the other hand indapamide, a thiazide like diuretic
whether used alone or in combination has not only shown a
consistent blood pressure lowering response but also improve-
ment in cardio-vascular outcomes. As a matter of fact, the HYVET
study had to be prematurely stopped due to a phenomenal 21%
reduction in all-cause mortality in patients receiving indapa-
mide.35 Further, there was also a 39% reduction in fatal strokes & a
64% reduction in heart failure. Long-term (1-year extension)
provided an even better reduction of 52% in all-cause mortality.36
In the PROGRESS trial, indapamide in combination with perindo-
pril reduced stroke by 43%.37 In the ADVANCE trial in diabetic
patients, a combination of indapamide and perindopril reduced all-
cause mortality by 14%, CV mortality by 18% and renal events by
21%.38 It further provides proof of metabolic safety of indapamide
on long-term basis; hemoglobin A1C (HbA1C) being maintained
over nearly 5 year period. In PATS, indapamide showed a
signiﬁcant reduction in secondary strokes by 29%.39 However, it
is important to note that these beneﬁts of indapamide are evident
even at the therapeutic dosage of either 2.5 mg immediate release
or the superior 1.5 mg sustained release. One of the reasons for the
salutatory effects of indapamide4 could be its predominantly
vascular effect. This minimizes the risk of diuretic related side
effects like electrolytic or metabolic disturbances. In a meta-
analysis by Thomopoulos et al. a separate analyses were done
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dose thiazides were found useful in reducing only composite end-
points (stroke and CAD and stroke, CAD, heart failure, and
cardiovascular death) but no individual end-points. Chlorthali-
done, on the other hand reduced stroke, CAD, heart failure and
their composites but not cardiovascular or all-cause mortality.20 It
was only low-dose indapamide which caused signiﬁcant risk
reduction in all components; stroke, composite of stroke and CHD,
and all-cause death.20 Another meta-analysis of ambulatory blood
pressure monitoring trials revealed that there was no evidence of
reduction in even combined CV outcomes (heart attacks, stroke,
death) with low doses of hydrochlorothiazide (12.5–25 mg).
Further, even the 24-h BP control (only 6.5/4.5 mmHg) was found
much inferior to other antihypertensive classes.40
7. Conclusions
Diuretics have remained ﬁrst line therapy in management of
uncomplicated primary hypertension since last several decades.
They are perhaps the only anti-hypertensive agents that have
demonstrated a robust and a consistent reduction not only in blood
pressure but also in cardio-vascular outcomes. Despite impressive
clinical data their use has been declining in recent years. This may
be related to concerns about tolerability and effect on metabolic
proﬁle at least by high-dose diuretics. Lower-dose diuretics
decrease side-effects but their action on cardio-vascular outcomes
also decreases. Lower dose hydrochlorothiazide is a weak anti-
hypertensive and does not seem to reduce cardio-vascular
outcomes. Low dose chlorthalidone is effective and also reduces
some cardiovascular outcomes but metabolic side-effects though
reduced, still persist. It is only low dose indapamide which is not
only effective but also consistently reduces cardiovascular out-
comes including all-cause mortality. In this context it is intriguing
that low dose diuretics particularly indapamide are still under-
utilized.
If you ever get close to a human and human behavior
Be ready, be ready to get confused and me and my here after
There’s deﬁnitely, deﬁnitely, deﬁnitely no logic to human
behavior
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